@article{oai:air.repo.nii.ac.jp:00002094,
 author = {矢野, 道広 and 蛇口, 美和 and 平井, 大士 and 深谷, 博志 and 久保田, 弘樹 and 近野, 勇樹 and 山田, 俊介 and 高橋, 勉 and Yano, Michihiro and Hebiguchi, Miwa and Hirai, Daishi and Fukaya, Hiroshi and Kubota, Hiroki and Konno, Yuki and Yamada, Shunsuke and Takahashi, Tsutomu},
 issue = {1},
 journal = {秋田医学},
 month = {Jun},
 note = {Kasabach-Merritt syndrome （KMS） is a consumptive coagulopathy associated with the presence of large hemangiomas. KMS has a high mortality rate of nearly 30% due to the development of serious bleeding tendencies, high output heart failure caused by arteriovenous shunt flow and respiratory failure caused by direct compression by large hemangiomas. Although several treatments are administered to treat KMS patients, including steroids, interferon, anti-neoplasm agents, propranolol and radiation therapy, there are no recommended management strategies, except for the use of steroid therapy as first-line therapy. We herein report two newborn cases of KMS with large congenital hemangiomas at birth. Although the laboratory findings of these cases were very similar, their clinical courses were significantly different. In one case, in spite of having introduced various treatments, it took more than one year for the laboratory findings to improve and stabilize.　However, in the other case, all laboratory findings normalized within three weeks after administering prednisolone only. We do not know why this disparity occurred. It is important to clarify the histopathological differences between apparently similar vascular tumors.},
 pages = {23--28},
 title = {出生時より巨大な血管腫を持つカサバッハ・メリット症候群の新生児2例 : 大きく異なった治療反応性},
 volume = {40},
 year = {2013}
}